Funds

Rydex Biotechnology Fund Class Investor

RYOIX

Rydex Biotechnology Fund Class Investor

Actions
  • Price (USD)84.14
  • Today's Change0.16 / 0.19%
  • 1 Year change13.81%
Data delayed at least 15 minutes, as of Dec 13 2019.
More ▼

Total returns on $10,000

5Y
Rydex Biotechnology Inv
Fund
Health
Morningstar category
MSCI ACWI NR USD
Benchmark index

Profile and investment

Fund typeOpen Ended Investment Company
Investment style (stocks)Market Cap: Mid
Investment Style: Growth
Morningstar categoryHealth
Launch date01 Apr 1998
Price currencyUSD
DomicileUnited States
SymbolRYOIX
Manager & start date
Michael Byrum
01 Apr 1998
Ryan Harder
14 Mar 2008
Pricing frequencyDaily
Total net assets
179.58m USD
As of Nov 30 2019
Net expense ratio1.46%
Front end load--
Deferred load--
Maximum Redemption Fee--
Min. initial investment2,500.00
USD
Min. additional investment--
Initial IRA1,000.00
USD
Additional IRA--
Available for saleUnited States
More ▼

Top 5 holdings

Top 5 holdings as a per cent of portfolio
43.95%32.01%0.00%32.01%
Category average% Net assets% Short% Long
Company1 year changePortfolio weightLong allocation
Amgen Inc
AMGN:NSQ
+19.85%7.63%
Abbvie Inc
ABBV:NYQ
+0.15%7.35%
Celgene Corp--5.90%
Gilead Sciences Inc
GILD:NSQ
-2.35%5.72%
Biogen Inc
BIIB:NSQ
-7.28%5.41%
Per cent of portfolio in top 5 holdings: 32.01%
Top 10 Holdings

Diversification

Asset type

Asset type

US stock97.50%
Cash3.26%
Non-US stock1.97%
US bond0.00%
Non-US bond0.00%
Other-2.73%

Top 5 sectors

Equity
Fixed income
Healthcare99.47%

Top 5 regions

United States97.50%
United Kingdom1.97%
Sector and region weightings are calculated using only long position holdings of the portfolio.
The performance data shown in tables and graphs on this page is calculated in USD of the fund/index/average (as applicable), on a Bid To Bid / Nav to Nav basis, with gross dividends re-invested on ex-dividend date. Past performance is not necessarily a guide to future performance; unit prices may fall as well as rise.
All managed funds data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
All data shown on this page, unless noted otherwise is Data Source and Copyright: Morningstar, Inc. 2019
All Rights reserved
© 2019 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.
Pricing for ETFs is the latest price and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.